On Rare Diseases: In Conversation with Dr Birgitte Volck, Non-Executive Board Director, OMass Therapeutics
28 February 2025
Birgitte Volck
Our new non-executive board member Birgitte Volck MD, PhD has decades of experience at companies developing new therapies to treat...
Read More
Remembering Prof. Graham Richards, Founding Chair of OMass Therapeutics
14 February 2025
Ros Deegan
It is with heavy hearts that we remember our dear friend Prof. Graham Richards, a colleague, mentor and the first...
Read More
Looking Back on 2024: A Year of Progress at OMass Therapeutics
17 December 2024
Ros Deegan
As 2024 draws to a close, it’s great to reflect on the progress we’ve made at OMass. It’s been a...
Read More
Too much of a good thing? New prospects for Congenital adrenal hyperplasia and Cushing’s disease
1 October 2024
Ali Jazayeri
As a class of signaling molecules, hormones regulate key aspects of physiology and behaviour across a multitude of organs. It...
Read More
From the feeble mouse to powerful therapeutics: Disrupting a key interaction in the pathway to systemic lupus
16 April 2024
Ali Jazayeri
Our immune system has evolved a defensive armamentarium to combat pathogens; critically including mechanisms that detect and respond to pathogen...
Read More
BIA Member spotlight: Meet OMass Therapeutics
19 March 2024
Ros Deegan
In this blog, Ros Deegan, CEO of OMass Therapeutics, a member of the BIA Board and a member of the Prime Ministers 2024 Business...
Read More
Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology
29 February 2024
Jim Geraghty
Thousands of rare diseases, most of genetic origin, were long ignored by a pharmaceutical industry that judged them too small...
Read More
2023 In Review
21 December 2023
Here we provide highlights of our progress and achievements during the year. As we bid farewell to 2023, we...
Read More
Employee Spotlight Series: Charlie Lay
20 November 2023
In this new series, we wanted to provide a spotlight on some of our employees! Culture is an important part...
Read More
Employee Spotlight Series: Srinath Krishnamurthy
29 September 2023
In this new series, we wanted to provide a spotlight on some of our employees! Culture is an important part...
Read More
Navigating ESG as a Biotech Company
24 April 2023
Miguel Silva
Environmental, social and governance (ESG) metrics are now ubiquitous in the reporting of public companies in the US and UK....
Read More
2022 In Review
23 December 2022
OMass Therapeutics
Here we provide highlights of our progress and achievements during the year. The past twelve months have included many notable...
Read More
Meet Our New Board Members: Diana Bernstein
3 August 2022
OMass Therapeutics
In this new series, we are introducing the new additions to the OMass Board of Directors following our latest round...
Read More
Meet Our New Board Members: Laia Crespo
27 June 2022
OMass Therapeutics
In this new series, we are introducing the new additions to the OMass Board of Directors following our latest round...
Read More
The OMass Mass-spec Club
22 June 2022
A.B. "Benjo" Paterson
As part of our all-hands meeting on the 16-17th of June 2022, we hosted a talent show to celebrate all...
Read More
Meet Our New Board Members: Scott Biller
16 June 2022
OMass Therapeutics
In this new series, we are introducing the new additions to the OMass Board of Directors following our latest round...
Read More
EDI, business success and jigsaw puzzles
30 May 2022
Hsin Loke
Written by: Hsin Loke Last week I was part of a panel at BioTrinity to discuss “Future Proofing Your Business...
Read More
